KCM
RNAC icon

Kennedy Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Kennedy Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-20,032
Closed -$1.6M – 716
2018
Q4 		$1.6M Sell
20,032
-4,971
-20% -$1.13M 0.04% 560
2018
Q3 		$11.7M Buy
25,003
+6,774
+37% +$2.72M 0.22% 127
2018
Q2 		$7.25M Buy
18,229
+15,221
+506% +$5.4M 0.14% 269
2018
Q1 		$920K Sell
3,008
-275
-8% -$78.3K 0.02% 670
2017
Q4 		$966K Buy
+3,283
New +$1.43M 0.02% 673

Other funds holding RNAC

Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kennedy Capital Management's RNAC Position: Q1 2019 in Review

Kennedy Capital Management sold out of Cartesian Therapeutics (RNAC) in Q1 2019, closing a stake of 20,032 shares — an estimated $1.6M sold.

Kennedy Capital Management first reported a position in RNAC in Q4 2017 and held it in 5 quarters. The position peaked at $11.7M in Q3 2018. 56 funds tracked by Wall St. Rank hold RNAC as of Q1 2019.

  • Kennedy Capital Management reported no remaining Cartesian Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Kennedy Capital Management sold 20,032 Cartesian Therapeutics shares in Q1 2019, an estimated $1.6M.
  • Kennedy Capital Management first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 5 quarters.
  • Kennedy Capital Management's Cartesian Therapeutics position peaked at $11.7M in Q3 2018.
  • 56 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2019.

Based on Kennedy Capital Management's 13F filing for Q1 2019, filed 13 May 2019.